Home /

Latest news

December 09, 2024

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new...

December 09, 2024

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and...

December 08, 2024

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys -CLL is...

AbbVie on Twitter

Looking for more news from AbbVie? Follow us on social media.

Press Kits

Our press kits are designed to provide journalists with a broad range of background information on our company.

Image library

Our media library provides you with our official AbbVie media including our logo, building and leaders.

Stay up to date on recent news, articles, and more.

News

Month Year

Get News Alerts by Email

June 23, 2009

ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock
June 22, 2009

ImmunoGen, Inc. Announces Exercise of Over-allotment Option
June 18, 2009

ImmunoGen, Inc. Prices Public Offering of Common Stock
June 17, 2009

ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock
June 11, 2009

ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound

Show per page

Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Societal impact

Our commitment to science is a commitment to better our society. Read our 2023 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2023 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?